192 results on '"Merscher, Sandra"'
Search Results
2. Radiation nephropathy: Mechanisms of injury and recovery in a murine model
3. Identification of Glomerular and Plasma Apolipoprotein M as Novel Biomarkers in Glomerular Disease
4. A Robust Phenotypic Screening Assay Utilizing Human Podocytes to Identify Agents that Modulate Lipid Droplets
5. Oxysterol-binding protein-like 7 deficiency leads to ER stress-mediated apoptosis in podocytes and proteinuria.
6. Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome
7. Normal and Dysregulated Sphingolipid Metabolism: Contributions to Podocyte Injury and Beyond
8. Mechanisms and Implications of Podocyte Autophagy in Chronic Kidney Disease
9. WCN24-1213 THE ROLE OF OXYSTEROL-BINDING PROTEIN LIKE 7 IN PODOCYTE HEALTH: IMPLICATIONS IN CHRONIC KIDNEY DISEASE PATHOPHYSIOLOGY
10. WCN24-1285 Interplay of OSBPL7 and HIF-1α in Hyperoxia-Induced Podocyte Dysfunction
11. Transplantation: platform to study recurrence of disease
12. Lipid deposition and metaflammation in diabetic kidney disease
13. Mechanisms and implications of podocyte autophagy in chronic kidney disease.
14. Sterol-O-acyltransferase-1 has a role in kidney disease associated with diabetes and Alport syndrome
15. Compounds targeting OSBPL7 increase ABCA1-dependent cholesterol efflux preserving kidney function in two models of kidney disease
16. FSGS Recurrence Collaboration: Report of a symposium
17. ATP-binding cassette A1 deficiency causes cardiolipin-driven mitochondrial dysfunction in podocytes
18. The podocyte: glomerular sentinel at the crossroads of innate and adaptive immunity
19. FSGS Recurrence Collaboration: Report of a Symposium.
20. Detection and Quantification of Lipid Droplets in Differentiated Human Podocytes
21. Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome
22. Author response: Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome
23. DACH1 as a multifaceted and potentially druggable susceptibility factor for kidney disease
24. Activation of Stimulator of IFN Genes (STING) Causes Proteinuria and Contributes to Glomerular Diseases
25. Mitochondrial Contribution to Inflammation in Diabetic Kidney Disease
26. Sphingomyelin phosphodiesterase acid like 3B (SMPDL3b) regulates Perilipin5 (PLIN5) expression and mediates lipid droplet formation
27. Editorial: Molecular mechanisms of proteinuria, volume II
28. Empagliflozin reduces renal lipotoxicity in experimental Alport syndrome
29. Direct Measurement of Free and Esterified Cholesterol Mass in Differentiated Human Podocytes: A TLC and Enzymatic Assay-Based Method
30. ABCA1 deficiency contributes to podocyte pyroptosis priming via the APE1/IRF1 axis in diabetic kidney disease.
31. Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury
32. Pharmacological targeting of actin-dependent dynamin oligomerization ameliorates chronic kidney disease in diverse animal models
33. Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome.
34. Implications of Sphingolipid Metabolites in Kidney Diseases
35. Adaptive and maladaptive roles of lipid droplets in health and disease
36. Glucose- and Non-Glucose-Induced Mitochondrial Dysfunction in Diabetic Kidney Disease
37. Molecular Mechanisms of Proteinuria, Volume II
38. Podocytopathy in Diabetes: A Metabolic Disorder
39. Use of Lipid-Modifying Agents for the Treatment of Glomerular Diseases
40. Lipid biology of the podocyte—new perspectives offer new opportunities
41. New insights into renal lipid dysmetabolism in diabetic kidney disease
42. Noninvasive assessment of radiation-induced renal injury in mice
43. Nicotine, smoking, podocytes, and diabetic nephropathy
44. Behavior of mice with mutations in the conserved region deleted in velocardiofacial/DiGeorge syndrome
45. APOL1 risk variants affect podocyte lipid homeostasis and energy production in focal segmental glomerulosclerosis
46. Discoidin domain receptor 1 activation links extracellular matrix to podocyte lipotoxicity in Alport syndrome
47. Sphingosine-1-Phosphate Metabolism and Signaling in Kidney Diseases
48. Lipid Metabolism Gets in a JAML during Kidney Disease
49. TBX1 is responsible for cardiovascular defects in velo-cardio-facial/DiGeorge syndrome
50. The Vicious Cycle of Renal Lipotoxicity and Mitochondrial Dysfunction
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.